Been looking at the medical device stocks space lately and there's actually some solid momentum building here for 2026. Last year threw a lot at the medtech industry - tariffs, supply chain chaos, geopolitical mess - but somehow the sector still managed to clock $584 billion in revenues with solid year-over-year growth. That's pretty resilient if you ask me.

What's catching my attention is how innovation is accelerating in specific pockets. AI integration into surgical systems, regenerative medicine breakthroughs, digital twins for personalized treatment - these aren't just buzzwords anymore, they're actually moving the needle on revenue. The FDA cleared over 250 AI-enabled medical devices through September 2025, which signals real adoption momentum.

Let me break down four medical device stocks worth watching if you're looking at this sector:

Intuitive Surgical keeps dominating the robotic surgery space. Their da Vinci 5 system just hit Japan and Europe, and the single-port version is gaining real traction. FDA cleared it for hernia repair and cholecystectomy recently. For 2026, they're guiding 14.3% revenue growth and 11.2% EPS growth - solid numbers with an ROE of 15.1%. This is the kind of medical device play that benefits from the shift toward minimally invasive procedures.

Insulет's momentum is harder to ignore. Omnipod revenues crossed $700 million in Q3 for the first time, driven by strong retention and new customer acquisition in both Type 1 and Type 2 diabetes markets. They just got FDA clearance for Omnipod 5 enhancements and are rolling out international versions with different CGM partners. 2026 guidance shows 19.8% revenue growth and 26.3% EPS growth - that's the kind of acceleration you want to see in medical device stocks.

Boston Scientific's WATCHMAN device continues to be the gold standard for left atrial appendage closure, and they're gaining share in electrophysiology with their FARAPULSE pulsed field ablation tech. Got NMPA approval in China too. Expecting 11.1% revenue growth and 13.6% EPS growth this year. Their historical five-year earnings growth of 21.8% beats the broader medtech average.

IDEXX Laboratories is the outlier here - they're focused on veterinary diagnostics but executing flawlessly. Their Catalyst platform keeps expanding, the inVue analyzer is one of their best product launches ever, and the Cancer Dx panel for early lymphoma detection in dogs is opening up a whole new market. Planning international expansion in 2026. Guidance shows 8.9% revenue growth and 11.6% EPS growth.

The broader medtech market is expected to grow at 5.94% CAGR through 2035, but these four companies are positioned to outpace that with their focus on innovation-driven segments. If you're building a healthcare tech portfolio, these medical device stocks deserve serious consideration for 2026.